To The Moon
Home
News
TigerAI
Log In
Sign Up
chanch
+Follow
Posts · 0
Posts · 0
Following · 0
Following · 0
Followers · 0
Followers · 0
chanch
chanch
·
2022-03-28
Doesnt sound good
Piper Sandler Downgrades Beyond Meat Inc. to Underweight
Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat
Piper Sandler Downgrades Beyond Meat Inc. to Underweight
看
2.26K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2022-03-14
No more booster jab pls!
Moderna Shares Soared Nearly 13% in Morning Trading
Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com
Moderna Shares Soared Nearly 13% in Morning Trading
看
2.45K
回复
Comment
点赞
5
编组 21备份 2
Share
Report
chanch
chanch
·
2021-09-19
Ok
Sorry, this post has been deleted
看
3.09K
回复
1
点赞
5
编组 21备份 2
Share
Report
chanch
chanch
·
2021-09-19
Ok
【老虎週刊】老虎社區一週十大精華文章
@老虎专刊：
嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 《街頭智慧》：羅傑斯的反內卷投資人生 發佈者：@MidasMike 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 都給IPhone13測評，我給股王蘋果做測評！ 發佈者：@不二說價值 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法 發佈者：
【老虎週刊】老虎社區一週十大精華文章
看
2.42K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-29
Time to some challenge!
Sorry, this post has been deleted
看
2.82K
回复
3
点赞
4
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-10
Not a surprise!
Sorry, this post has been deleted
看
3.17K
回复
2
点赞
4
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-10
Oh wow!
Sorry, this post has been deleted
看
2.66K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-05
Settling time
Coursera fell 3% after soaring 21% yesterday
(Aug 5) Coursera fell 3% after soaring 21% yesterday. the company have reported Q2 2021 financial r
Coursera fell 3% after soaring 21% yesterday
看
3.13K
回复
1
点赞
1
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-04
Roller coaster ride!
Sorry, this post has been deleted
看
2.66K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-07-28
Wow
Sorry, this post has been deleted
看
2.38K
回复
Comment
点赞
7
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583728210057163","uuid":"3583728210057163","gmtCreate":1620638378496,"gmtModify":1621435601582,"name":"chanch","pinyin":"chanch","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":237,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9010449813,"gmtCreate":1648458655734,"gmtModify":1676534340169,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Doesnt sound good","listText":"Doesnt sound good","text":"Doesnt sound good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9010449813","repostId":"1111470167","repostType":4,"repost":{"id":"1111470167","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648456625,"share":"https://ttm.financial/m/news/1111470167?lang=en_US&edition=fundamental","pubTime":"2022-03-28 16:37","market":"us","language":"en","title":"Piper Sandler Downgrades Beyond Meat Inc. to Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1111470167","media":"Tiger Newspress","summary":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat","content":"<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler Downgrades Beyond Meat Inc. to Underweight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler Downgrades Beyond Meat Inc. to Underweight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-28 16:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111470167","content_text":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).","news_type":1,"symbols_score_info":{"BYND":0.9}},"isVote":1,"tweetType":1,"viewCount":2262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9032949328,"gmtCreate":1647266968723,"gmtModify":1676534209870,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"No more booster jab pls! ","listText":"No more booster jab pls! ","text":"No more booster jab pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032949328","repostId":"1186570327","repostType":4,"repost":{"id":"1186570327","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1647265373,"share":"https://ttm.financial/m/news/1186570327?lang=en_US&edition=fundamental","pubTime":"2022-03-14 21:42","market":"us","language":"en","title":"Moderna Shares Soared Nearly 13% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186570327","media":"Tiger Newspress","summary":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com","content":"<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine," said Stephen Hoge, M.D., President of Moderna. "This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV."</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field," said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. "We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV."</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shares Soared Nearly 13% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shares Soared Nearly 13% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine," said Stephen Hoge, M.D., President of Moderna. "This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV."</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field," said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. "We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV."</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186570327","content_text":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).\"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,\" said Stephen Hoge, M.D., President of Moderna. \"This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.\"The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.\"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,\" said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. \"We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.\"The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355448,"gmtCreate":1631981462884,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887355448","repostId":"2168757119","repostType":4,"isVote":1,"tweetType":1,"viewCount":3089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355513,"gmtCreate":1631981419632,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887355513","repostId":"887339719","repostType":1,"repost":{"id":887339719,"gmtCreate":1631972463127,"gmtModify":1676530680476,"author":{"id":"35433028694349","authorId":"35433028694349","name":"老虎专刊","avatar":"https://static.laohu8.com/e0b93d50cf0df54ce7b1b746f78db36c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"35433028694349","idStr":"35433028694349"},"themes":[],"title":"【老虎週刊】老虎社區一週十大精華文章","htmlText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","listText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","text":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 《街頭智慧》：羅傑斯的反內卷投資人生 發佈者：@MidasMike 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 都給IPhone13測評，我給股王蘋果做測評！ 發佈者：@不二說價值 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法 發佈者：","images":[{"img":"https://static.tigerbbs.com/3d5e2fc85108344477e4c0796d4f7359","width":"1717","height":"924"},{"img":"https://static.tigerbbs.com/99f2c14a32d644799c78e85ffdbce509","width":"755","height":"429"},{"img":"https://static.tigerbbs.com/a05c777fdd742a2cdc135436ad862e92","width":"928","height":"619"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887339719","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":12,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813819894,"gmtCreate":1630167062418,"gmtModify":1676530237453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Time to some challenge! ","listText":"Time to some challenge! ","text":"Time to some challenge!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/813819894","repostId":"2162907389","repostType":4,"isVote":1,"tweetType":1,"viewCount":2820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868203,"gmtCreate":1628569899302,"gmtModify":1703508301835,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Not a surprise! ","listText":"Not a surprise! ","text":"Not a surprise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/896868203","repostId":"1181756731","repostType":4,"isVote":1,"tweetType":1,"viewCount":3166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868980,"gmtCreate":1628569860940,"gmtModify":1703508300862,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Oh wow! ","listText":"Oh wow! ","text":"Oh wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896868980","repostId":"1186259544","repostType":4,"isVote":1,"tweetType":1,"viewCount":2657,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899837205,"gmtCreate":1628172944607,"gmtModify":1703502574255,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Settling time ","listText":"Settling time ","text":"Settling time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899837205","repostId":"1132594719","repostType":4,"repost":{"id":"1132594719","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628171470,"share":"https://ttm.financial/m/news/1132594719?lang=en_US&edition=fundamental","pubTime":"2021-08-05 21:51","market":"us","language":"en","title":"Coursera fell 3% after soaring 21% yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132594719","media":"Tiger Newspress","summary":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial r","content":"<p>(Aug 5) Coursera fell 3% after soaring 21% yesterday. </p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coursera fell 3% after soaring 21% yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoursera fell 3% after soaring 21% yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5) Coursera fell 3% after soaring 21% yesterday. </p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUR":"Coursera, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132594719","content_text":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .\nOn the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.\nWait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.\nWhen analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.\nSo in the case of Coursera, analysts forecast that the company would lose $0.11 per sharepro forma.But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company'sGAAPloss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company'spro formaloss for the quarter was only $0.05 per share.\nOr in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"","news_type":1,"symbols_score_info":{"COUR":0.9}},"isVote":1,"tweetType":1,"viewCount":3133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890077515,"gmtCreate":1628071841737,"gmtModify":1703500663435,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Roller coaster ride! ","listText":"Roller coaster ride! ","text":"Roller coaster ride!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890077515","repostId":"1120792298","repostType":4,"isVote":1,"tweetType":1,"viewCount":2658,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801981924,"gmtCreate":1627479524768,"gmtModify":1703490752094,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801981924","repostId":"1102507343","repostType":4,"isVote":1,"tweetType":1,"viewCount":2376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}